Business Description
![Merck & Co Inc Merck & Co Inc logo](https://static.gurufocus.com/logos/0C000008C5.png?14)
Merck & Co Inc
NAICS : 325412
SIC : 2834
ISIN : US58933Y1055
Compare
Compare
Traded in other countries / regions
MRK.USAMRCK34.BrazilMRK.MexicoMRK.ArgentinaMRK.Chile6MK.GermanyMRK.Peru1MRKX.ItalyMRK.Austria6MKd.UKMRK.FranceMRK.Ukraine IPO Date
1949-04-20Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.16 | |||||
Equity-to-Asset | 0.38 | |||||
Debt-to-Equity | 0.85 | |||||
Debt-to-EBITDA | 3.81 | |||||
Interest Coverage | 4.07 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.48 | |||||
Beneish M-Score | -2.99 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13 | |||||
3-Year EBITDA Growth Rate | -12.2 | |||||
3-Year EPS without NRI Growth Rate | -20.2 | |||||
3-Year FCF Growth Rate | 16.1 | |||||
3-Year Book Growth Rate | 14.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 93.02 | |||||
Future 3-5Y Total Revenue Growth Rate | 5.7 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 35.79 | |||||
9-Day RSI | 39.59 | |||||
14-Day RSI | 42.26 | |||||
6-1 Month Momentum % | 11.89 | |||||
12-1 Month Momentum % | 12.32 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.25 | |||||
Quick Ratio | 0.99 | |||||
Cash Ratio | 0.22 | |||||
Days Inventory | 142.81 | |||||
Days Sales Outstanding | 63.67 | |||||
Days Payable | 83.79 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.42 | |||||
Dividend Payout Ratio | 1.38 | |||||
3-Year Dividend Growth Rate | 6.1 | |||||
Forward Dividend Yield % | 2.45 | |||||
5-Year Yield-on-Cost % | 3.56 | |||||
Shareholder Yield % | 1.46 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 74.37 | |||||
Operating Margin % | 7.99 | |||||
Net Margin % | 3.76 | |||||
FCF Margin % | 17.98 | |||||
ROE % | 5.63 | |||||
ROA % | 2.17 | |||||
ROIC % | 3.79 | |||||
ROC (Joel Greenblatt) % | 20.67 | |||||
ROCE % | 6.22 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 140.27 | |||||
Forward PE Ratio | 14.64 | |||||
PE Ratio without NRI | 58.18 | |||||
Shiller PE Ratio | 35.66 | |||||
PS Ratio | 5.23 | |||||
PB Ratio | 7.92 | |||||
Price-to-Tangible-Book | 197.25 | |||||
Price-to-Free-Cash-Flow | 29.09 | |||||
Price-to-Operating-Cash-Flow | 21.76 | |||||
EV-to-EBIT | 67.89 | |||||
EV-to-Forward-EBIT | 13.24 | |||||
EV-to-EBITDA | 38.67 | |||||
EV-to-Forward-EBITDA | 11.99 | |||||
EV-to-Revenue | 5.66 | |||||
EV-to-Forward-Revenue | 5.4 | |||||
EV-to-FCF | 31.46 | |||||
Price-to-Projected-FCF | 2.26 | |||||
Price-to-Median-PS-Value | 1.2 | |||||
Price-to-Graham-Number | 22.67 | |||||
Earnings Yield (Greenblatt) % | 1.47 | |||||
FCF Yield % | 3.45 | |||||
Forward Rate of Return (Yacktman) % | 1.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:MRK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Merck & Co Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 61,402 | ||
EPS (TTM) ($) | 0.9 | ||
Beta | 0.33 | ||
Volatility % | 18.17 | ||
14-Day RSI | 42.26 | ||
14-Day ATR ($) | 2.993767 | ||
20-Day SMA ($) | 129.5685 | ||
12-1 Month Momentum % | 12.32 | ||
52-Week Range ($) | 99.14 - 134.63 | ||
Shares Outstanding (Mil) | 2,532.81 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Merck & Co Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Merck & Co Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Merck & Co Inc Frequently Asked Questions
What is Merck & Co Inc(MRK)'s stock price today?
The current price of MRK is $126.24. The 52 week high of MRK is $134.63 and 52 week low is $99.14.
When is next earnings date of Merck & Co Inc(MRK)?
The next earnings date of Merck & Co Inc(MRK) is 2024-07-30.
Does Merck & Co Inc(MRK) pay dividends? If so, how much?
The Dividend Yield %  of Merck & Co Inc(MRK) is 2.42% (As of Today), Highest Dividend Payout Ratio of Merck & Co Inc(MRK) was 1.96. The lowest was 0.37. And the median was 0.5. The  Forward Dividend Yield % of Merck & Co Inc(MRK) is 2.45%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |